



ASX/Media Release

21 January 2019

Receipt of \$2.057m R&D Tax Incentive Rebate

Melbourne, Australia; 21 January 2019: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the Company has received an R&D Tax Incentive Rebate from the Australian Taxation Office of \$2.057m for the 2017/2018 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

For more information, please contact:

General enquiries

Michael Kotsanis
Acrux Limited
CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

Investor enquiries

Anthony England
Vesparum Capital

P: +61 3 8582 4800

E: acrux@vesparum.com

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au